Ekso BionicsCHRN

The company reports its latest numbers today. Analysts expect a loss of about 6 cents per share. This report is an important check on the company's plan to sell off its old medical business and use the money to buy more computer servers for its AI leasing arm.

We are watching for any updates on that sale and the progress of the server expansion. The company is currently spending more cash than it brings in to fund this shift, so the details on how it plans to pay for these new data centers will be the most important part of the update.

See the full quarter, and how our tracked metrics did

The company is expected to report its latest quarterly numbers today. Analysts are looking for a loss of about 6 cents per share. This report is particularly important because the business is in the middle of a total reset, trying to sell off its old bionics division to focus entirely on renting out specialized computer power for AI.

We are watching for any updates on that sale and how much cash the company is spending to build out its new server fleets. Because one parent company controls 96 percent of the stock, these strategic shifts can happen quickly, but they also leave regular shareholders with very little say in how the business is run.

See the full quarter, and how our tracked metrics did

Key highlights

• Profitability showing improvement: The net loss, which is the money the company lost after all expenses, improved 31% year over year to $1.4 million. This was driven by a significant reduction in operating expenses, which fell to $3.9 million compared to $4.8 million a year ago.
• Gross margins widening: Gross margin, the percentage of revenue left after paying for the cost of the devices, rose to 60.3% from 53.5% last year. The company achieved this by lowering device costs and selling more high-margin Enterprise Health products.
• Revenue recovering quickly: Sales grew 2% year over year to $4.2 million, but they more than doubled from the previous quarter, jumping 105%. This rebound suggests the company is moving past a difficult second quarter.
• Strategic sale exploration: The company announced it is looking for a strategic transaction, which could mean selling all or part of the business. Management did not set a specific timetable for this review but warned that any deal would likely require a shareholder vote.
• Cash position tightening: ChronoScale ended the quarter with $2.7 million in cash, down from $4.5 million at the start of the year. While losses are narrowing, the company still needs to manage its remaining funds carefully while it explores a potential sale.

Our take: This was a encouraging rebound quarter for ChronoScale. The 105% sequential revenue jump and significantly better margins show the business can stabilize its losses. However, the decision to explore a total sale or a new line of business suggests management sees limited paths for the current strategy on its own.